Trials / Unknown
UnknownNCT05598788
Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies
Development of a Microsampling Approach for Personalized Monitoring of Kinase Inhibitor Targeted Therapies
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 360 (estimated)
- Sponsor
- Rennes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.
Detailed description
The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib. Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Measurement of drug concentrations | Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample |
Timeline
- Start date
- 2023-03-03
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2022-10-28
- Last updated
- 2023-05-03
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05598788. Inclusion in this directory is not an endorsement.